Ligands and Cofactors Required for RORgt Function in the Immune System
免疫系统中 RORgt 功能所需的配体和辅因子
基本信息
- 批准号:8676594
- 负责人:
- 金额:$ 13.31万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-08-15 至 2014-11-02
- 项目状态:已结题
- 来源:
- 关键词:AcidsAgonistAutoimmune DiseasesAutoimmunityBindingBiochemicalBiological AssayBiological FactorsCD4 Positive T LymphocytesCandidate Disease GeneCell Differentiation processCell LineCell LineageCellsCholesterolCholesterol HomeostasisCo-ImmunoprecipitationsCollaborationsComplementComplexCytokine GeneDetectionDevelopmentDiseaseDouble-Stranded RNADrosophila genomeDrosophila genusEnzymesFetusGene ExpressionGene TargetingGenerationsGenesGeneticGenetic TranscriptionHelper-Inducer T-LymphocyteHomeostasisHumanImmune systemInflammatoryInflammatory ResponseInsectaInterleukin-17InterventionIntestinesLamina PropriaLibrariesLigand Binding DomainLigandsLipidsLymphoidLymphoid CellLymphoid FollicleLymphoid TissueMalignant NeoplasmsMammalian CellMass Spectrum AnalysisMediator of activation proteinModelingMusMutationNuclear Orphan ReceptorNuclear ReceptorsOrthologous GenePathway interactionsPeptidesPhysiologicalProcessProductionProteinsRNA InterferenceRefractoryReporterResearch InstituteRoleStructureStructure of aggregated lymphoid follicle of small intestineSystemSystems DevelopmentT-LymphocyteTestingYeastsbasecandidate validationcofactorcytokinegenome wide association studygenome-wideimprovedin vivolymph nodesmicrobialnovel strategiesoverexpressionpathogenreceptor structure functionresponsescreeningsmall moleculethymocytetranscription factoryeast two hybrid system
项目摘要
The orphan nuclear receptor RORyt has critical roles in immune system development, homeostasis, and responses to microbial pathogens. This transcription factor is expressed only in lymphoid lineage cells, including immature thymocytes, lymphoid tissue inducer (Lti) cells, and T helper cells that produce the inflammatory cytokine IL-17 (Th17 cells). RORyt has essential functions in each of these cells. It is required for the survival of CD4+8+ thymocytes and, hence, for the selection of an appropriate T cell repertoire; it is essential for the differentiation of Lti cells that induce formation of lymph nodes and Peyer's patches in the fetus and of cryptopatches and isolated lymphoid follicles in the post-natal intestine; and it is required for the differentiation of Th17 cells from naive CD4+ T lymphocytes. Th17 cells have recently been shown to be major mediators of disease in several models for autoimmunity in the mouse, and there is accumulating evidence that they have similar roles in humans. We found the absence of RORyt in T cells results in reduced IL-17 production in response to relevant cytokines and in the loss of most Th17 cells in the intestinal lamina propria, where they are normally most abundant. In addition, mice lacking RORyt are refractory to the induction of several autoimmune diseases. These findings suggest that RORyt may be an attractive target for pharmacological intervention in multiple inflammatory conditions.
Our understanding of the mechanism of action of RORyt is currently limited, and little is known about how its transcriptional activity is regulated. There is compelling evidence that RORyt, like other nuclear receptors, is regulated by binding of a ligand. In preliminary studies, we have shown that mutations in the putative ligand binding domain abrogate the ability of RORyt to induce transcriptional activity or to direct cytokine gene expression in T cells. We have found that RORyt has transcriptional activity in Drosophila S2 cells, and have exploited this observation to perform a genome-wide RNA interference screen. This screen has been complemented by studies with overexpression or RNAi knockdown of genes involved in lipid biosynthetic pathways that have pointed us towards candidate ligands. Based on these findings and on other preliminary studies, we propose the following aims: (1) to further characterize biosynthetic pathways to pinpoint enzymes involved in generation of a RORyt ligand, using both mammalian and insect cell-based systems; (2) to validate candidate ligands using both biochemical/biophysical (e.g., binding assays and co-crystal structures) and functional approaches (e.g. mouse and human Th17 cell polarization); and (3) to characterize other factors that influence RORyt transcriptional activity, including mouse and human orthologs of genes identified in the Drosophila RNAi screen and molecules identified by co-immunoprecipitation of complexes and by interaction screening with appropriate libraries in yeast. Together, these studies will provide a better understanding of the mechanism of action of RORyt and will facilitate new strategies for therapy in autoimmune diseases.
孤儿核受体RORyt在免疫系统发育、体内平衡和对微生物病原体的反应中起着关键作用。该转录因子仅在淋巴系细胞中表达,包括未成熟胸腺细胞、淋巴组织诱导剂(Lti)细胞和产生炎症细胞因子IL-17 (Th17细胞)的T辅助细胞。RORyt在这些细胞中都有重要的功能。它是CD4+8+胸腺细胞存活所必需的,因此,选择合适的T细胞库;它对Lti细胞的分化至关重要,从而诱导胎儿的淋巴结和Peyer's斑块的形成,以及出生后肠内的隐斑和分离淋巴滤泡的形成;它是Th17细胞从初始CD4+ T淋巴细胞分化所必需的。Th17细胞最近被证明是几种小鼠自身免疫模型中疾病的主要介质,并且越来越多的证据表明它们在人类中具有类似的作用。我们发现,T细胞中RORyt的缺失导致IL-17产生减少,以响应相关细胞因子,并导致肠固有层中大多数Th17细胞的丢失,而肠道固有层通常是Th17细胞最丰富的地方。此外,缺乏RORyt的小鼠对几种自身免疫性疾病的诱导具有难治性。这些发现表明,RORyt可能是多种炎症条件下药物干预的一个有吸引力的靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(5)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Dan Littman其他文献
Dan Littman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Dan Littman', 18)}}的其他基金
Determinants of induced Treg and inflammatory Th17 cell balance in response to potentially pathogenic microbiota
诱导 Treg 和炎症 Th17 细胞平衡响应潜在致病微生物群的决定因素
- 批准号:
10372223 - 财政年份:2021
- 资助金额:
$ 13.31万 - 项目类别:
Mechanism of microbiota-mediated potentiation of checkpoint blockade efficacy in lung cancer
微生物群介导的肺癌检查点阻断功效增强机制
- 批准号:
10686041 - 财政年份:2021
- 资助金额:
$ 13.31万 - 项目类别:
Determinants of induced Treg and inflammatory Th17 cell balance in response to potentially pathogenic microbiota
诱导 Treg 和炎症 Th17 细胞平衡响应潜在致病微生物群的决定因素
- 批准号:
10579197 - 财政年份:2021
- 资助金额:
$ 13.31万 - 项目类别:
Mechanism of microbiota-mediated potentiation of checkpoint blockade efficacy in lung cancer
微生物群介导的肺癌检查点阻断功效增强机制
- 批准号:
10299034 - 财政年份:2021
- 资助金额:
$ 13.31万 - 项目类别:
Determinants of induced Treg and inflammatory Th17 cell balance in response to potentially pathogenic microbiota
诱导 Treg 和炎症 Th17 细胞平衡响应潜在致病微生物群的决定因素
- 批准号:
10185533 - 财政年份:2021
- 资助金额:
$ 13.31万 - 项目类别:
Mechanism of microbiota-mediated potentiation of checkpoint blockade efficacy in lung cancer
微生物群介导的肺癌检查点阻断功效增强机制
- 批准号:
10436388 - 财政年份:2021
- 资助金额:
$ 13.31万 - 项目类别:
Roles of DDX5 and its associated long non-coding RNAs in RORgt-mediated host immune system functions
DDX5及其相关长非编码RNA在RORgt介导的宿主免疫系统功能中的作用
- 批准号:
9179587 - 财政年份:2015
- 资助金额:
$ 13.31万 - 项目类别:
Roles of DDX5 and its associated long non-coding RNAs in RORgt-mediated host immune system functions
DDX5及其相关长非编码RNA在RORgt介导的宿主免疫系统功能中的作用
- 批准号:
9010056 - 财政年份:2015
- 资助金额:
$ 13.31万 - 项目类别:
Dendritic Cell Restriction and Innate Immune Sensing of HIV Infection
HIV 感染的树突状细胞限制和先天免疫感应
- 批准号:
7841122 - 财政年份:2010
- 资助金额:
$ 13.31万 - 项目类别:
Dendritic Cell Restriction and Innate Immune Sensing of HIV Infection
HIV 感染的树突状细胞限制和先天免疫感应
- 批准号:
8134886 - 财政年份:2010
- 资助金额:
$ 13.31万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 13.31万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 13.31万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 13.31万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 13.31万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 13.31万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 13.31万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 13.31万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 13.31万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 13.31万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 13.31万 - 项目类别:














{{item.name}}会员




